Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market, 2023 - Market is Anticpated to Reach $5.56 Billion

Dublin, May 23, 2017 -- Research and Markets has announced the addition of the "Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market - Analysis and Forecast 2017-2023 (Focus on Device Type, Drug Type, Market Share Analysis, Patent Landscape and Country Analysis)" report to their offering.

The global market is expected to reach $5.56 billion by 2023. With the advent of generics & OTC products the growth in GERD drugs market has decreased. The absence of patent protected & new regulatory approved medicines are the restraints for the growth of this market. The global GERD drugs market has a low growth potential in future and will account to $5.38 billion by 2023.

The GERD therapy market is an already established market, in which a number of the drugs have lost patent protection. The market is driven by significant unmet medical need. The prospective growth is expected to be driven by favorable factors such as increased prevalence among world population, limited number of treatment options, need of new regulatory approved medication, and increase in the world geriatric population. Future market growth is particularly expected in Asia Pacific region where the prevalence of GERD therapy is increasing gradually.

Acquisition of Torax Medical in February 2017, will certainly facilitate Ethicon to offer LINX, a small implantable alternative to patients and ultimately strengthen Johnson & Johnson position in GERD market. Also, with the approval of Mederi's Stretta Therapy for GERD in China, Stretta therapy is now available to China population. These recent developments highpoint the advancements taking place in the GERD market.

The increasing demand of medical devices have led various companies to focus on new product developments and innovations, and further carry out other market developments as well. In this market, major companies are adopting partnerships and collaboration strategies to strengthen their position among other players.

The key players in the device market are Endogastric Solutions, Medigus Ltd., Medtronic Plc, Carbon Medical technologies, Johnson & Johnson etc. The gold standard in surgery for the treatment of GERD is Nissen Fundoplication.

Key questions answered in the report:

• What will be the market size is in terms of revenue from 2016-2023 for the global GERD Drugs and Devices market?
• What the market size are in terms of revenue for devices such LINX management system, MUSE, Stretta, Bravo reflux management system and Digitrapper in the global GERD Drugs and Devices market?
• Which device type will dominate the market during the forecast period?
• What is the market size in terms of revenue generated from different drug class with respect to geographical regions in the global GERD Drugs and Devices market?
• What are the major market drivers, challenges and opportunities of the global GERD Drugs and Devices market?
• What will be the market shares of drugs & devices of the global GERD market by 2023?
• How will each segment of the GERD Drugs and Devices market grow over the forecast period and how much revenue will these account for in 2023?
• How will the market share of the leading companies change in 2016 and which country will lead the market in 2017?
• What are the new strategies adopted by the existing market players to make a mark in the industry?
• Which regions will lead the global GERD Drugs and Devices market by the end of the forecast period?

Key Topics Covered:

Executive Summary

1 Report Scope & Methodology

2 Market Overview

4 Drug Pipeline Analysis

5 Competitive Landscape

6 Industry Analysis

7 Global GERD Drug Market by Route of Administration, 2016-2023 (Qualitative)

8 Global GERD Drug Market by Dosage Form, 2016-2023 (Qualitative)

9 Global GERD Market by Drug Type, 2016-2023

10 Global GERD Market by Device Type, 2016-2023

11 Global GERD Drug and Devices Market by Region, 2016-2023

12 Company Profiles

• AstraZeneca PLC
• Boston Scientific Corporation
• Cempra Inc.
• Eisai Co., Ltd.
• EndoGastric Solutions Inc.
• EndoStim Inc.
• GlaxoSmithKline Plc
• Ironwood Pharmaceuticals, Inc.
• Jeil pharmaceutical Co. Ltd.
• Johnson & Johnson
• Mederi Therapeutics Inc.
• Medigus Ltd.
• Medtronic Inc.
• Merck & CO., Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceuticals Industries Limited.
• Torax Medical
• Valeant Pharmaceuticals International, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/9g7nfc/global_gastro

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Gastrointestinal Drugs